FOLLOWING ITS ACQUISITION BY ONCODNA, INTEGRAGEN HAS UNDERGONE A COMPLETE OVERHAUL AND IS NOW READY TO EMBARK ON NEW PROJECTS IN THE FIELDS OF CANCER AND GENETIC DISEASES.
Since the successful tender offer in November 2020, IntegraGen has been working hand in hand with OncoDNA the consolidation of their teams and services. The acquisition has brought together two companies with complementary expertise. While IntegraGen is a leading player in DNA sequencing services, OncoDNA is a world-renowned company specializing in precision medicine for cancer treatment. The Belgian company offers comprehensive biomarker tests to support clinical decision-making and guide towards the most appropriate treatments. OncoDNA also offers liquid biopsy enabling real-time monitoring of patients' response to treatment and the progression of their disease. Since its inception in 2012, OncoDNA has disrupted technological innovation in the field of molecular profiling and has been recognized for its continued exponential growth.
Within the OncoDNA group, IntegraGen will leverage the power of next-generation sequencing to facilitate theaccess to therapeutic innovation in the hospital environment and exert a greater influence on the quality of patient care. This integration has given rise to a European leader in precision medicine, now able to offer a wide range of products and services. unique, highly integrated portfolio covering the needs of every link in the value chainThese range from translational research and drug development to patient treatment and follow-up.
IN FIGURES :
- An experienced team of more than 100 employeesOur team of geneticists, clinicians and biostatisticians is here to support your projects.
- Molecular profiling charts and clinical recommendations for 60,000 cancer patients
- Our proprietary database of over 4,500,000 genetic variants, 1,150 cancer drugs, data from 7,000 clinical trials
- 2 partner laboratories in Europe and the United States
- An international presence in over 50 countries
- A pioneer in comprehensive biomarker testing (2014) and liquid biopsy (2016)
June 16, 2021
Share :
Leave a Reply